GB0900555D0 - New methods - Google Patents

New methods

Info

Publication number
GB0900555D0
GB0900555D0 GBGB0900555.4A GB0900555A GB0900555D0 GB 0900555 D0 GB0900555 D0 GB 0900555D0 GB 0900555 A GB0900555 A GB 0900555A GB 0900555 D0 GB0900555 D0 GB 0900555D0
Authority
GB
United Kingdom
Prior art keywords
new methods
new
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0900555.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onxeo DK
Original Assignee
Topotarget AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget AS filed Critical Topotarget AS
Priority to GBGB0900555.4A priority Critical patent/GB0900555D0/en
Publication of GB0900555D0 publication Critical patent/GB0900555D0/en
Priority to JP2011544847A priority patent/JP2012515143A/en
Priority to PCT/EP2010/000077 priority patent/WO2010081662A2/en
Priority to MX2011007373A priority patent/MX2011007373A/en
Priority to CA2749051A priority patent/CA2749051A1/en
Priority to EP10701451A priority patent/EP2387397A2/en
Priority to US12/657,160 priority patent/US20100190694A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0900555.4A 2009-01-14 2009-01-14 New methods Ceased GB0900555D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0900555.4A GB0900555D0 (en) 2009-01-14 2009-01-14 New methods
JP2011544847A JP2012515143A (en) 2009-01-14 2010-01-11 Methods for identifying patients who respond well to cancer therapy
PCT/EP2010/000077 WO2010081662A2 (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment
MX2011007373A MX2011007373A (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment.
CA2749051A CA2749051A1 (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment
EP10701451A EP2387397A2 (en) 2009-01-14 2010-01-11 Methods for identifying patients who will respond well to cancer treatment
US12/657,160 US20100190694A1 (en) 2009-01-14 2010-01-14 Methods for identifying patients who will respond well to cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0900555.4A GB0900555D0 (en) 2009-01-14 2009-01-14 New methods

Publications (1)

Publication Number Publication Date
GB0900555D0 true GB0900555D0 (en) 2009-02-11

Family

ID=40379541

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0900555.4A Ceased GB0900555D0 (en) 2009-01-14 2009-01-14 New methods

Country Status (7)

Country Link
US (1) US20100190694A1 (en)
EP (1) EP2387397A2 (en)
JP (1) JP2012515143A (en)
CA (1) CA2749051A1 (en)
GB (1) GB0900555D0 (en)
MX (1) MX2011007373A (en)
WO (1) WO2010081662A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103458896B (en) * 2011-04-01 2016-02-10 施瑞修德制药公司 Be used for the treatment of the method for cancer
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
WO2017070441A1 (en) * 2015-10-23 2017-04-27 Icahn School Of Medicine At Mount Sinai Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor
CN108685947A (en) * 2017-04-11 2018-10-23 上海尚泰生物技术有限公司 Colorectal cancer hepatic metastases primary tumor and transfer stove match model

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
BR9914779A (en) * 1998-10-13 2001-07-03 Fujisawa Pharmaceutical Co Compound wf27082, process for its production, pharmaceutical composition containing it, strain of funds belonging to the genus acremonium, compound having histone deacetylase inhibiting activity, process for its production, its method and use
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
BR0010017A (en) * 1999-04-28 2002-06-11 Univ Texas Compositions and processes for the treatment of cancer by selective vegf inhibition
JP2003514904A (en) * 1999-11-23 2003-04-22 メチルジーン インコーポレイテッド Histone deacetylase inhibitor
ATE310719T1 (en) * 2000-09-29 2005-12-15 Topotarget Uk Ltd CARBAMINIC ACID DERIVATIVES CONTAINING AN AMIDE GROUP AS HDAC INHIBITORS
AU9013101A (en) * 2000-09-29 2002-04-22 Prolifix Ltd Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
JP2004517334A (en) * 2001-01-09 2004-06-10 ノバルティス アクチエンゲゼルシャフト Rapid method for screening in vivo activity of compounds
WO2002074298A1 (en) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
NZ531153A (en) * 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7767390B2 (en) * 2001-11-20 2010-08-03 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
MXPA04006717A (en) * 2002-01-11 2004-11-10 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer.
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
JP2005525345A (en) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Methods for treating TRX-mediated diseases
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
CA2478094C (en) * 2002-03-04 2010-11-23 Aton Pharma, Inc. Methods of inducing terminal differentiation
US7495022B2 (en) * 2002-04-11 2009-02-24 Sk Chemicals Co., Ltd. α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JP2005530734A (en) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Combination therapy for the treatment of cancer
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20060089322A1 (en) * 2002-05-01 2006-04-27 Mark Vincent Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7606215B2 (en) * 2003-04-07 2009-10-20 Paul Poniatowski Audio/visual information dissemination system
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
RU2356547C2 (en) * 2003-08-26 2009-05-27 Мерк ЭйчДиЭйСи Рисерч ЛЛС Cancer therapy with using hdac inhibitors
ATE353107T1 (en) * 2003-08-28 2007-02-15 Hoffmann La Roche DEPENDENCE OF SYMPTOM-FREE SURVIVAL OF 5-FU TREATED COLON CANCER PATIENTS ON THE RATIO OF THE MRNA EXPRESSION LEVEL OF THYMIDINE PHOSPHORYLASE AND DIHYDROPYRIMIDINE DEHYDROGENASE
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2005051430A1 (en) * 2003-11-14 2005-06-09 Per Sonne Holm Novel use of adenoviruses and nucleic acids that code for said viruses
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
AU2005218769B8 (en) * 2004-02-27 2012-04-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Pharmacodynamic assays using flow cytometry
EP1591109B1 (en) * 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
EP1787657A1 (en) * 2004-08-06 2007-05-23 Ono Pharmaceutical Co., Ltd. Therapeutic agent for psychoneurotic disease
JP4946861B2 (en) * 2004-08-09 2012-06-06 アステラス製薬株式会社 Hydroxamide compound having inhibitory activity of histone deacetylase (HDAC)
US8889742B2 (en) * 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
EP1830864A2 (en) * 2004-12-31 2007-09-12 Per Sonne Holm E1-minus adenoviruses and use thereof
AU2006207325B2 (en) * 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
WO2006082428A2 (en) * 2005-02-03 2006-08-10 Topotarget Uk Limited Combination therapies using hdac inhibitors
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
JP5108750B2 (en) * 2005-05-13 2012-12-26 トポターゲット ユーケー リミテッド Pharmaceutical formulation of HDAC inhibitor
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007024574A2 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
JP2009507846A (en) * 2005-09-07 2009-02-26 プレキシコン，インコーポレーテッド PPAR active compounds
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US8828392B2 (en) * 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
JP5349056B2 (en) * 2006-02-22 2013-11-20 ４エスツェー アクチェンゲゼルシャフト Indropyridines as Eg5 kinesin modulators
CN101389629A (en) * 2006-02-22 2009-03-18 4Sc股份公司 Indolepyridines as EG5 kinesin modulators
US8338416B2 (en) * 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008011603A2 (en) * 2006-07-20 2008-01-24 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
CA2669675A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008094319A2 (en) * 2007-02-01 2008-08-07 The Board Of Regents Of The University Of Texas Sytem Methods and compositions of trail-death receptor agonists/activators
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
WO2008116163A1 (en) * 2007-03-22 2008-09-25 Oregon Health & Science University Therapeutic drug combinations for treatment of b-cell malignancies
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2008154402A2 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
WO2010081662A2 (en) 2010-07-22
JP2012515143A (en) 2012-07-05
US20100190694A1 (en) 2010-07-29
WO2010081662A3 (en) 2010-09-23
MX2011007373A (en) 2011-08-08
CA2749051A1 (en) 2010-07-22
EP2387397A2 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
DK3023438T3 (en) Anti-gitr-antistoffer
DK2442650T4 (en) Sublingualt apomorfin
GB0907413D0 (en) Novel methods
EP2462514A4 (en) Greenbooks
GB0909645D0 (en) Methods
GB0907350D0 (en) Methods
EP2515891A4 (en) 3-keto-n-propargyl-1-aminoindan
EP2519921A4 (en) Call-tracking
GB0901001D0 (en) Methods
DK2464943T3 (en) Systemintegration
GB0912685D0 (en) Methods
GB0900555D0 (en) New methods
GB0912159D0 (en) Methods
GB0907601D0 (en) Novel methods
GB0900319D0 (en) Hydrocharger
EP2510125A4 (en) Hyperprimers
GB0912624D0 (en) Methods
GB0904209D0 (en) Methods
GB0901232D0 (en) Methods
GB0900280D0 (en) Methods
AU4240P (en) Tuckerbox xTriticosecale
AU4925P (en) Bonscawi Scaevola aemula
AU4926P (en) Bonscalib Scaevola aemula
EG26256A (en) Oxyga
GB0900671D0 (en) Tugbug

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)